MedTrace Logo

Type 3 Von Willebrand International Registries Inhibitor Prospective Study

NCT02460458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 265

Last updated 2024-12-27

Study results available
· View outcomes & findings →

Summary

International Registries and Prospective Study on Type 3 Von Willebrand's Disease (VWD3), aimed to assess number, types and risk factors for bleeding and the efficacy and safety of plasma-derived and/or recombinant Von Willebrand Factor (VWF) concentrates used to treat VWD patients.

Conditions

  • Type 3 Von Willebrand's Disease

Interventions

DRUG

Von Willebrand Factor

Replacement therapy with plasma-derived and/or recombinant VWF concentrates on-demand or under prophylaxis therapeutic scheme.

Sponsors & Collaborators

  • Sintesi Research Srl

    collaborator INDUSTRY

  • Fondazione Angelo Bianchi Bonomi

    lead OTHER

Principal Investigators

  • Augusto B. Federici, MD · Hematology and Transfusion Medicine, L. Sacco University Hospital, University of Milan, Via G. B. Grassi, 74 20157 Milan, Italy

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-05
Primary Completion
2023-03-28
Completion
2023-04-17

Countries

  • Finland
  • France
  • Germany
  • Hungary
  • Iran
  • Italy
  • Netherlands
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02460458 on ClinicalTrials.gov